<DOC>
	<DOCNO>NCT02499497</DOCNO>
	<brief_summary>This research study study use target therapy call LY SARM , investigational drug new class molecule call Selective Androgen Receptor Modulators ( SARMs ) possible improvement quality life participant undergone radical prostatectomy . Androgens group hormone play role male trait reproductive activity . The name study intervention involve study : - LY2452473</brief_summary>
	<brief_title>A Selective Androgen Receptor Modulator Symptom Management Prostate Cancer</brief_title>
	<detailed_description>This research study Phase II clinical trial . Phase II clinical trial test safety effectiveness investigational intervention learn whether intervention work treat specific disease . `` Investigational '' mean intervention study . The FDA ( U.S. Food Drug Administration ) approve LY SARM/LY2452473 treatment disease . In research study , investigator study new investigational drug call LY SARM ( LY2452473 ) . Concerns potential adverse effect testosterone prostate lead development molecule call SARMs ( Selective Androgen Receptor Modulators ) . This investigational drug may improve sexual function , quality life , muscle bone mass men prostate cancer . This molecule choose evidence show may help improve sexual function aid improvement muscle mass influence prostate .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Inclusion Criteria Age 19 year age old History prostate cancer Stage pT2 N0 , M0 lesion ( If AJCC stag available medical record , investigator infer stag base extensive review pathology report ) Combined Gleason score &lt; 7 ( 3+4 ) Radical prostatectomy two year ago Preoperative PSA &lt; 10 ng/ml ( preoperative PSA available medical record , lowrisk subject Gleason score 6 ( 3+3 ) least 5 year surgery consider enrollment ) PSA &lt; 0.1 ng/mL use assay functional sensitivity 0.1 ng/mL least two year radical prostatectomy Serum testosterone , measure LCMS/MS , &lt; 300 mg/dL and/or free testosterone equilibrium dialysis &lt; 60 pg/mL . * DISFMII score â‰¤20 , fatigue ( FACITF score &lt; 30 ) , physical dysfunction ( selfreported difficulty walk 1/4 mile climb two flight stair , short physical performance battery score 4 9 ) . Ability understand willingness sign write informed consent document . Agree use adequate contraception prior receive study drug , duration study participation , 4 month completion LY SARM administration . Exclusion Criteria History radiation monotherapy History androgen deprivation therapy Use testosterone , DHEA , estrogens , GnRH analog , antiandrogens , spironolactone , ketoconazole , rhGH , megesterol acetate within past 6 month Use prednisone 20 mg daily equivalent dos glucocorticoids two week within past 6 month Use Clarithromycin , telithromycin , chloramphenicol , itraconazole , nefazodone , cobicistat within past 6 month Use penile implant , vacuum pump device , intracavernosal injection Hematocrit &gt; 50 % Serum creatinine &gt; 2.5 mg/dL AST great 3x ULN ALT great 3x ULN Hemoglobin A1c &gt; 7.5 % Body mass index ( BMI ) &gt; 40 kg/m2 Diabetes require insulin therapy Severe untreated sleep apnea ( treatment define therapy CPAP , BiPAP , ASV , positive air pressure device ) Uncontrolled heart failure ( NYHA class 3 4 ) History HIV Myocardial infarction within last 3 month Acute coronary syndrome within last 3 month Revascularization surgery within last 3 month Stroke within last 3 month Diagnosed schizophrenia bipolar disorder untreated depression Not appropriate study base physician discretion</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Prostate Cancer</keyword>
</DOC>